CClinicalTrials.gg
CompletedNCT03829709Updated Aug 13, 2020

Electromiography Study in the Respiratory Muscle Training in Human Lymphotropic Virus Type 1

An interventional study of Rehabilitation in HTLV-I Infections, sponsored by Universidade Metodista de Piracicaba. Completed at 1 site in Brazil. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-08-13.

Sponsored by Universidade Metodista de Piracicaba · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The main objective of the research will be to analyze, through surface electromyography, the impact of inspiratory muscle training before a supervised home training protocol in patients with human T-cell lymphotropic virus type 1 (HTLV-1). For this, a clinical, longitudinal, prospective, quantitative and single center trial will be carried out, aiming at home inspiratory muscle training lasting 5 weeks, 3 times a week, 30 minutes daily through the IMT Threshold, with 14 volunteers enrolled in the Laboratory of Studies in Functional Rehabilitation (LAERF) of the Federal University of Pará (UFPA). They will be classified as the manifestation of Tropical Spastic Paraparesis / Myelopathy (PET / MAH) for GP (PET / MAH probable) and GD (PET / MAH definitive) groups, obeying inclusion criteria. For characterization of expiratory flow rates and flows, as well as respiratory muscle strength, they will be submitted to spirometry and manovacuometry, pre, per, and post treatment, respectively. For the analysis of the electromyographic activity, the diaphragm, parasternal and sternocleidomastoid muscles will be counted in the follow-up during the analysis of inspiratory muscle strength, as well as once a week during the conduction of the inspiratory muscle training protocol. The collected data will be stored in a Microsoft Office Excel® 2010 worksheet and then submitted to statistical analysis using the Bioestat 5.0® program, adopting a standard error of 5%. The theoretical support of the research will have a bibliographical survey of scientific articles collected during the design of the project, and the accomplishment of the research. It is expected to map, through the surface electromyographic study, the impact of respiratory muscle training at a distance on the inspiratory muscle strength of patients with HTLV-I virus with probable or definitive PET / MAH.

Read the detailed description

Human T-lymphotropic viruses, HTLV (Human Lymphotrophic Virus T), are retroviruses, which stand out as type 1 (HTLV-1) and type 2 (HTLV-2), the former being the etiologic agent of serious organ diseases such as leukemia adult T-cell lymphoma (ATLL), a neurological disorder, Tropical Spastic Paraparesis / HTLV-I-associated myelopathy (PET / HAM) and other non-malignant ophthalmologic, dermatological, rheumatic and osteomyelitis non-malignant disorders. For HTLV-2 it has not yet separated with some disease.

The highest prevalence of virus is found in countries of the Caribbean, South America, Melanesia Islands, West Africa and Japan. Brazil is an endemic country for infection and prevalence varies from state to state, being highest in Bahia, Pernambuco and Pará. The form of sexual transmission, hematologic for blood transfusions or accompanied by contaminated needles, mother-to-child verticalization, the passage of the lymphocyte infected by breast milk and also in the perinatal period.

The mechanism of the disease comes from the infection of several types of cells, such as T and B lymphocytes, monocytes and fibroblasts. However, its tropism is by TCD4 + cells. The form of contamination is cell-cell, thus being transferred from infected material to uninfected cells, modifying the immune system, as well as cell cells.

The main characteristic of HTLV infection is that in most cases the virus persists asymptomatic and undetectable by the immune system per year or until death in about 98% of the patients, while the hosts are able to transmit the virus. There are still no basic surveys on how severe forms of symptoms of graves occur in those infected.

In this context, when the individual becomes symptomatic, he is affected by chronic infection that may be associated with disabling diseases that compromise quality of life, such as the neurological disease PET-MAH. The onset is insidious with frequent changes in gait and urinary symptoms, mainly affecting the lower limbs such as spasticity, hyperreflexia, sensory-motor dysfunctions such as neuropathic or nociceptive pain, paresis, paralysis and paresthesia, urinary bladder disorders, muscle weakness and low back pain. The early diagnosis of motor complications in the face of the onset of neurological disease also contributes to the prevention of the installation of motor sensory sequelae if the physiotherapeutic treatment is established early. According to this reference, one of the aspects of preventive care refers to the functional autonomy correlated with physical conditioning in order to increase the strength and / or endurance of the skeletal muscles.

In this way, the possibility of morphological and functional changes in the respiratory system is also highlighted. With preventive therapeutic possibilities, the respiratory muscle training (TMR) appears to this indicator with reference to the maximum inspiratory and expiratory pressures (PiMáx and PeMáx). This procedure directly reflects on the patient's functionality, having as guideline the conduction of training protocols. The protocol should be conducted at least three days weekly frequently twice daily.

One tool to evaluate muscular behavior during TMR is surface electromyography (EMGs), which consists of a non-invasive detection of the muscular electrical activity by which it is presented graphically. It is constituted by the transcription of the sum of the electrical activity of all the active muscle fibers, through the positioning of electrodes on the skin. Thus, in order to verify the muscular activity of the respiratory dynamics related to inspiration, the main groups are the diaphragm, parasternal intercostal, sternocleidomastoid, abdominal rectus.

Therefore, the training requires time, availability and greater displacement of the patient to the outpatient treatment units, thus causing difficulties in adherence to the proposed therapy. To that end, it has been proposed ways that facilitate such conduction, such as home treatments, which, in most cases, the patient is supervised by the physiotherapist at least once a week presently followed by distance monitoring.

02

Conditions studied

  • HTLV-I Infections
03

In context

Lead sponsor

Universidade Metodista de Piracicaba is the lead sponsor of 34 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • volunteers of both sexes
  • HTLV-1 positive serology with definitive or probable PET / MAH

Exclusion criteria

Exclusion Criteria:

  • pulmonary diseases
  • serious comorbidities such as heart disease and uncontrolled arterial hypertension
  • cognitive alterations that impede the conduction of the protocol
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Intervention Group

    The inspiratory muscle training (IMT) will be performed in the morning shift for 30 minutes, 3 times a week for 5 weeks. The first training session each week will be held at the LAERF under the direct supervision of the investigator and the other two home-based training sessions under the supervisor's distance supervision. They will receive the Threshold® IMT linear loading device, and guidelines for handling, posture and asepsis. The initial training load for each participant will be adjusted to 25% of PiMáx. Participants will be trained and instructed to do the exercise program on their own at home. Once a week, during the return to the laboratory the researcher will determine the new values for load (1st week 25%, 2nd week 35%, 3rd week 40%, 4th week 45%, 5th week 50%).

    Other: Rehabilitation

Interventions

  • OtherRehabilitation

    The first training session each week will be held at the LAERF under the direct supervision of the investigator and the other two home-based training sessions under the supervisor's distance supervision. They will receive the Threshold® IMT linear loading device, and guidelines for handling, posture and asepsis. The initial training load for each participant will be adjusted to 25% of PiMáx. Participants will be trained and instructed to do the exercise program on their own at home. Once a week, during the return to the laboratory the researcher will determine the new values for load (1st week 25%, 2nd week 35%, 3rd week 40%, 4th week 45%, 5th week 50%).

06

What researchers measure

Primary outcomes

  1. Inspiratory and expiratory muscle force

    The evaluation of respiratory muscle strength will be performed by measuring the maximal inspiratory pressure (PiMáx) and expiratory (PeMAx) measurements with manovacuometer (+ - 300cmH2O). In order to perform the measurement of PiMáx and PeMáx, referring to inspiratory and expiratory muscle strength respectively. The values can range from 0 to 300 cmH2O, being 0 no strength and 300 maximum respiratory muscle strength.

    Time frame: Five weeks

07

Study locations

1 site
  • Universidade da Amazônia
    Belém, Pará 66060902, Brazil
08

References and documents

Publications

  • Magno Falcao LF, Falcao ASC, Medeiros Sousa RC, Vieira WB, de Oliveira RTM, Normando VMF, Dias GADS, Santos MCS, Rocha RSB, Yoshikawa GT, Koyama RVL, Fujihara S, Correa VAC, Fuzii HT, Quaresma JAS. CT Chest and pulmonary functional changes in patients with HTLV-associated myelopathy in the Eastern Brazilian Amazon. PLoS One. 2017 Nov 2;12(11):e0186055. doi: 10.1371/journal.pone.0186055. eCollection 2017. Erratum In: PLoS One. 2017 Dec 27;12(12):e0190436. doi: 10.1371/journal.pone.0190436. PubMed 29095831 ↗
  • Levy J, Prigent H, Bensmail D. Respiratory rehabilitation in multiple sclerosis: A narrative review of rehabilitation techniques. Ann Phys Rehabil Med. 2018 Jan;61(1):38-45. doi: 10.1016/j.rehab.2017.06.002. Epub 2017 Nov 8. PubMed 29128525 ↗
  • Nakamura T. HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP): the role of HTLV-I-infected Th1 cells in the pathogenesis, and therapeutic strategy. Folia Neuropathol. 2009;47(2):182-94. PubMed 19618340 ↗
  • Nikoletou D, Man WD, Mustfa N, Moore J, Rafferty G, Grant RL, Johnson L, Moxham J. Evaluation of the effectiveness of a home-based inspiratory muscle training programme in patients with chronic obstructive pulmonary disease using multiple inspiratory muscle tests. Disabil Rehabil. 2016;38(3):250-9. doi: 10.3109/09638288.2015.1036171. Epub 2015 Apr 17. PubMed 25885668 ↗
  • Sa KN, Macedo MC, Andrade RP, Mendes SD, Martins JV, Baptista AF. Physiotherapy for human T-lymphotropic virus 1-associated myelopathy: review of the literature and future perspectives. J Multidiscip Healthc. 2015 Feb 23;8:117-25. doi: 10.2147/JMDH.S71978. eCollection 2015. PubMed 25759588 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03829709
Lead sponsor
Universidade Metodista de Piracicaba
Responsible party
Rodrigo Santiago Barbosa Rocha, Phd (Director of Human Movement Department, Universidade Metodista de Piracicaba) — Principal investigator
First posted
Feb 4, 2019
Start date
Jan 30, 2019
Primary completion
Jul 23, 2020
Completion
Jul 23, 2020
Last update
Aug 13, 2020

Study contacts

João S Oliveira, phd
study chair · Universidade Metodista de Piracicaba

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion